Lopez, Juanita http://orcid.org/0000-0001-8321-4212
Lai-Kwon, Julia
Molife, Rhoda
Welsh, Liam
Tunariu, Nina
Roda, Desamparados
Fernández-García, Paula http://orcid.org/0000-0002-8128-7028
Lladó, Victoria
McNicholl, Adrian G.
Rosselló, Catalina A.
Taylor, Richard J.
Azaro, Analía
Rodón, Jordi http://orcid.org/0000-0001-6467-3632
Sludden, Julieann
Veal, Gareth J.
Plummer, Ruth http://orcid.org/0000-0003-0107-1444
Urruticoechea, Ander
Lahuerta, Ainhara
Mujika, Karmele
Escribá, Pablo V.
Article History
Received: 28 November 2022
Revised: 25 June 2023
Accepted: 28 June 2023
First Online: 24 July 2023
Competing interests
: VL, PF-G, AM, CAR and PVE work for and are Laminar Pharmaceuticals shareholders, the sponsor of this study. RJT is a consultant to Laminar Pharmaceuticals. The remaining authors declare no competing interests.
: All patients participating in the study provided written informed consent. The study got a favourable opinion from the Ethics Committees of the three centres participating in the study. Those were the Central Research Ethics Committee from London, Euskadi and Vall d’Hebrón. REC Reference is 13/LO/0062. The trial was conducted in compliance with local and national regulations and in accordance with the Declaration of Helsinki.
: The written informed consent signed by all patients in the study includes authorisation of medical publications.